Literature DB >> 25962396

Establishment and characterization of triple drug resistant head and neck squamous cell carcinoma cell lines.

Sindhu Valiyaveedan Govindan1, Safeena Kulsum1, Ramanan Somasundara Pandian2, Debashish Das2, Mukund Seshadri3, Wesley Hicks4, Moni Abraham Kuriakose1, Amritha Suresh1.   

Abstract

Resistance to chemotherapy leading to poor outcome and survival remains a challenge for developing strategies for therapeutic interventions in all types of cancer, including head and neck cancer. In vitro chemoresistant cell line models are an indispensable resource towards delineating the mechanisms involved in drug resistance/response and for the development of novel drugs. Current treatment for head and neck cancer includes chemotherapy with cisplatin, docetaxel and 5-fluorouracil (5-FU) and the response rates to these drugs in patients is 60-80%. The present study aimed to generate head and neck cancer triple drug-resistant cell lines in an effort towards elucidating the mechanisms underlying chemoresistance and providing a resourceful tool for drug design. Using two head and neck squamous cell carcinoma cell lines, Hep-2 (larynx) and CAL-27 (oral cavity), the present study sequentially exposed these cells to increasing concentrations of the combination of docetaxel, cisplatin and 5-FU (TPF) to generate triple drug-resistant cells, termed Hep-2 TPF resistant (TPFR) and CAL-27 TPFR. The effect of the drug treatments on the cell viability, apoptosis, cell cycle and the expression of genes associated with multidrug resistance were analyzed in the parental cells and drug-resistant counterparts.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25962396     DOI: 10.3892/mmr.2015.3768

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  3 in total

Review 1.  Moving towards personalised therapy in head and neck squamous cell carcinoma through analysis of next generation sequencing data.

Authors:  M Giefing; M Wierzbicka; K Szyfter; J C Brenner; B J Braakhuis; R H Brakenhoff; C R Bradford; J A Sorensen; A Rinaldo; J P Rodrigo; R P Takes; A Ferlito
Journal:  Eur J Cancer       Date:  2016-02-04       Impact factor: 9.162

Review 2.  Potentials of lncRNA-miRNA-mRNA networks as biomarkers for laryngeal squamous cell carcinoma.

Authors:  Yan Lv; Yanhua Wang; Zhikai Zhang
Journal:  Hum Cell       Date:  2022-10-01       Impact factor: 4.374

3.  Identification of MAEL as a promoter for the drug resistance model of iPSCs derived from T-ALL.

Authors:  Xuemei Chen; Feiqiu Wen; Zhu Li; Weiran Li; Meiling Zhou; Xizhuo Sun; Pan Zhao; Chang Zou; Tao Liu
Journal:  Cancer Med       Date:  2022-04-29       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.